1. Home
  2. WST vs BEKE Comparison

WST vs BEKE Comparison

Compare WST & BEKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WST
  • BEKE
  • Stock Information
  • Founded
  • WST 1923
  • BEKE 2001
  • Country
  • WST United States
  • BEKE China
  • Employees
  • WST N/A
  • BEKE N/A
  • Industry
  • WST Medical/Dental Instruments
  • BEKE Real Estate
  • Sector
  • WST Health Care
  • BEKE Finance
  • Exchange
  • WST Nasdaq
  • BEKE Nasdaq
  • Market Cap
  • WST 18.9B
  • BEKE 23.2B
  • IPO Year
  • WST N/A
  • BEKE 2020
  • Fundamental
  • Price
  • WST $256.66
  • BEKE $20.40
  • Analyst Decision
  • WST Strong Buy
  • BEKE Strong Buy
  • Analyst Count
  • WST 8
  • BEKE 6
  • Target Price
  • WST $329.43
  • BEKE $24.97
  • AVG Volume (30 Days)
  • WST 539.7K
  • BEKE 6.4M
  • Earning Date
  • WST 10-23-2025
  • BEKE 08-26-2025
  • Dividend Yield
  • WST 0.34%
  • BEKE 1.76%
  • EPS Growth
  • WST N/A
  • BEKE N/A
  • EPS
  • WST 6.68
  • BEKE 0.46
  • Revenue
  • WST $2,960,200,000.00
  • BEKE $14,384,647,393.00
  • Revenue This Year
  • WST $6.28
  • BEKE $16.76
  • Revenue Next Year
  • WST $6.02
  • BEKE $12.40
  • P/E Ratio
  • WST $38.47
  • BEKE $43.41
  • Revenue Growth
  • WST 2.90
  • BEKE 32.52
  • 52 Week Low
  • WST $187.43
  • BEKE $13.41
  • 52 Week High
  • WST $352.33
  • BEKE $26.05
  • Technical
  • Relative Strength Index (RSI)
  • WST 58.07
  • BEKE 68.32
  • Support Level
  • WST $254.35
  • BEKE $19.57
  • Resistance Level
  • WST $264.06
  • BEKE $20.33
  • Average True Range (ATR)
  • WST 5.88
  • BEKE 0.46
  • MACD
  • WST 0.41
  • BEKE 0.17
  • Stochastic Oscillator
  • WST 66.99
  • BEKE 83.59

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About BEKE KE Holdings Inc (each representing three)

KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2024, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.

Share on Social Networks: